In patients with urticaria, when is systemic hydrocortisone indicated and what is the recommended dosing regimen?

Hydrocortisone for Urticaria

Systemic hydrocortisone (or other corticosteroids) should be reserved for specific acute urticaria scenarios—severe laryngeal edema, anaphylaxis, or when symptoms are intolerable and require rapid control—but should NOT be used routinely or long-term in chronic urticaria. 1

When Systemic Corticosteroids Are Indicated

Acute Urticaria Settings

Parenteral hydrocortisone is indicated as an adjunct in:

• Severe laryngeal edema (though its action is delayed compared to epinephrine) 1
• Anaphylaxis (as adjunctive therapy, not primary treatment) 1

Oral corticosteroids (prednisolone preferred over hydrocortisone) may shorten the duration of acute urticaria when:

• Symptoms are intolerable despite antihistamines 1
• Rapid clinical response is needed 2

Important caveat: Recent high-quality evidence shows that adding corticosteroids to antihistamines in acute urticaria provides only modest benefit. For patients with high antihistamine responsiveness (95.8% improvement rate), corticosteroids add only 2.2% absolute benefit (NNT=45), while increasing adverse events by 15% (NNH=9) 3. Two out of three RCTs found no improvement when adding prednisone to cetirizine/levocetirizine 4.

Chronic Urticaria Settings

Corticosteroids have very limited indications:

• Short tapering courses (3-4 weeks) for urticarial vasculitis or severe delayed pressure urticaria 1
• Short courses (7-14 days) if symptoms are uncontrolled by antihistamines and rapid response is needed, but only as a bridge to other therapies 2

Long-term oral corticosteroids should NOT be used in chronic urticaria (Strength of recommendation A) except in very selected cases under regular specialist supervision 1. The 2022 international guidelines notably removed corticosteroids from the chronic urticaria treatment algorithm entirely 5.

Recommended Dosing Regimens

Acute Urticaria (Oral)

• Prednisolone 50 mg daily for 3 days in adults, though lower doses are often effective 1
• Alternative: Short 7-14 day course if needed 2

Parenteral Hydrocortisone (Emergency Use)

Per FDA labeling 6:

• Initial dose: 100-500 mg IV/IM, depending on severity
• Can be repeated at 2,4, or 6-hour intervals based on response
• Administer IV over 30 seconds (100 mg) to 10 minutes (500+ mg)
• Duration: Continue only until stabilized, usually not beyond 48-72 hours
• If therapy must continue beyond 48-72 hours, consider switching to methylprednisolone to avoid sodium retention

Pediatric Dosing

• 0.56 to 8 mg/kg/day in 3-4 divided doses (20-240 mg/m²/day) 6

Critical Clinical Algorithm

For Acute Urticaria:

1. Start with second-generation H1-antihistamine (e.g., cetirizine, levocetirizine)
2. If life-threatening (laryngeal edema/anaphylaxis): Give IM epinephrine FIRST, then add parenteral hydrocortisone as adjunct
3. If severe but not life-threatening: Consider short oral corticosteroid course (3 days) only if symptoms are intolerable
4. Recognize that corticosteroids provide minimal added benefit in most cases and increase adverse effects by 15% 3

For Chronic Urticaria:

1. Second-generation H1-antihistamine at standard dose
2. If inadequate control after 2-4 weeks: Updose antihistamine up to 4-fold 5
3. If still inadequate: Add omalizumab 300 mg every 4 weeks (NOT corticosteroids) 5
4. Reserve corticosteroids only for specific subtypes (urticarial vasculitis, severe delayed pressure urticaria) with short tapering courses 1

Common Pitfalls to Avoid

• Do not use prolonged corticosteroid therapy for chronic spontaneous urticaria—this leads to significant adverse effects without addressing the underlying autoimmune/autoreactive pathophysiology 5, 1
• Do not delay escalation to omalizumab in chronic urticaria by continuing ineffective antihistamine or corticosteroid therapy 5, 7
• Remember hydrocortisone's delayed onset in anaphylaxis—epinephrine is the life-saving intervention 1
• Avoid hypernatremia with prolonged high-dose hydrocortisone (>48-72 hours); switch to methylprednisolone if needed 6
• Monitor for adverse effects: The NNH is only 9 for corticosteroid-related adverse events in urticaria 3

The evidence strongly supports a restrictive approach to corticosteroid use in urticaria, with the most recent 2022 guidelines removing them from the chronic urticaria algorithm entirely and emphasizing antihistamine updosing followed by omalizumab as the evidence-based pathway 5.